Altai Protocol Library
1041 protocols and counting
All protocols with references and links
All protocols reviewed by a Medical Oncologist/Hematologist
All protocols in major guidelines included
Ability to create your own protocols
New indication: Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer
Study: Multicenter, open-label, phase 1/2 trial Cisplatin ineligible, local advanced/metastatic urothelial carcinoma Enfortumab vedotin + pembrolizumab q21 (n=45) Efficacy: CRR: 15.6% [7 of 45 pts] ORR: 73.3% [33 of 45
New Reference: Atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150)
Study: Phase III, multicenter, randomized, double-blind trial Previously untreated unresectable stage IIIc or stage IV melanoma Atezolizumab (n=256) vs. PBO + vemurafenib + cobiventinib (n=258) Efficacy: mOS: 39.0 vs 25.8
New Indication: Cemiplimab-rwlc in combination with platinum-based chemotherapy for non-small cell lung cancer (EMPOWER-Lung-3)
Study: Double-blind, placebo-controlled, phase 3 study Untreated advanced or metastatic NSCLC Group A (Cemiplimab + chemotherapy (n=312)) vs. group B (chemotherapy alone (n=154)) Efficacy: mOS : 21.9 vs. 13.0 mos
New indication: Olutasidenib for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation
Study: Phase 1/2, multicenter, open-label Treatment-naive and Relapsed or refractory AML; MDS with an IDH1 mutation Olutasidenib monotherapy (n=32) vs. combination with Azacitidine (n=46) Efficacy: Relapsed or refractory AML: ORR
New Protocol – A Phase 2 Study of Pemigatinib in Patients with Myeloid/Lymphoid Neoplasms with Fibroblast Growth Factor Receptor 1 Rearrangement 8 (FIGHT-203)
Study: Phase 2, open label, multicenter trial Myeloid/Lymphoid Neoplasms 28 patients ≥1 prior therapy Pemigatinib 13.5 mg daily (2 wks; 1 wk off) No prior therapy Pemigatinib 13.5
New Protocol – Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
Study: Randomised, triple-blind, phase 3 trial Stage IB (tumours of ≥4 cm in diameter), II, or IIIA NSCLC Pembrolizumab 200 mg (590) or placebo (587) / 3 weeks-18 cycles Efficacy:
New Reference: Pembrolizumab as adjuvant therapy in completely resected stage IIB or IIC melanoma
Study: Double-blind, randomised, phase 3 study (KEYNOTE-716) Newly diagnosed, completely resected stage IIB or IIC melanoma Pembrolizumab (n=483) or placebo (n=486) Efficacy: RFS @ 20.9 mos: 85% vs. 76% [
New Drug: Relatlimab and Nivolumab in Advanced Melanoma
Study: Double-blind, randomized Phase II-III trial Untreated metastatic or unresectable melanoma Relatlimab and nivolumab vs nivolumab alone Efficacy: mPFS: 10.1 vs 4.6 mos (HR:0.75; P=0.006) 12 months PFS: 47.7% vs
New Drug: Tebentafusp-tebn for metastatic uveal melanoma
Study: Open-label Phase III trial Untreated HLA-A*02:01-positive patients with metastatic uveal melanoma Tebentafusp or the investigator’s choice of therapy with single-agent pembrolizumab, ipilimumab, or dacarbazine Efficacy: Median OS: 21.7 vs.